A screen by Kost-Alimova et al. 1 suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). A screen by Kost-Alimova et al. 1 suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
All Keywords
【초록키워드】 COVID-19, ARDS, coronavirus, acute respiratory distress syndrome, Lung injury, outcome, acute lung injury, MUC1, Screen, fostamatinib, respiratory tract, respiratory, inhibitor, acute respiratory distress, respiratory distress, syndrome, treat, inhibit, SYK, 【제목키워드】 repurposing, fostamatinib, combat,
【초록키워드】 COVID-19, ARDS, coronavirus, acute respiratory distress syndrome, Lung injury, outcome, acute lung injury, MUC1, Screen, fostamatinib, respiratory tract, respiratory, inhibitor, acute respiratory distress, respiratory distress, syndrome, treat, inhibit, SYK, 【제목키워드】 repurposing, fostamatinib, combat,
Kost-Alimova 외의 화면 1은 FDA 승인 SYK 억제제 포스타마티닙이 기도에서 MUC1을 억제하고 급성 호흡 곤란 증후군(ARDS) 및 급성 폐 손상(ALI)을 포함한 코로나바이러스 COVID-19의 심각한 결과를 치료할 가능성이 있음을 시사합니다. Kost-Alimova 외의 화면 1은 FDA 승인 SYK 억제제 포스타마티닙이 기도에서 MUC1을 억제하고 급성 호흡 곤란 증후군(ARDS) 및 급성 폐 손상(ALI)을 포함한 코로나바이러스 COVID-19의 심각한 결과를 치료할 가능성이 있음을 시사합니다.